RxDoctor Payments Data

Dale Smith, MD

Pulmonary Disease · Kansas City, MONPI 1881199271

Payments from drug & device makers

$1,169in general payments, 2019–2025

Across 39 payments — averaging $29.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$394
  • AstraZeneca$212
  • GSK$155
  • Insmed, Inc.$144
  • Olympus America Inc.$92
  • Regeneron Healthcare Solutions, Inc.$76
  • plus $96 from 4 others

What the payments were for

  • Food & beverage$1,169100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,169 in reported general payments places this provider in the 40th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$25,864
Medicare patients
100
Services billed
200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$14,522
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$11,228
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$8,541
Bevespi AerosphereGlycopyrrolate/Formoterol Fum11$4,670
Albuterol Sulfate HfaAlbuterol Sulfate33$961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere$212$19,19226 claims
GSKAnoro Ellipta$155$11,22822 claims
Boehringer IngelheimStiolto Respimat$22$8,54111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →